Salim MD - Oncternal Therapeutics Chief Officer
Insider
Salim MD is Chief Officer of Oncternal Therapeutics
| Age | 55 |
| Phone | 858 434 1113 |
| Web | https://www.oncternal.com |
Oncternal Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7645) % which means that it has lost $0.7645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4986) %, meaning that it created substantial loss on money invested by shareholders. Oncternal Therapeutics' management efficiency ratios could be used to measure how well Oncternal Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Oncternal Therapeutics currently holds 318 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Oncternal Therapeutics has a current ratio of 10.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oncternal Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Todd MBA | Armata Pharmaceuticals | 61 | |
| Nancy Pecota | Adverum Biotechnologies | 64 | |
| Hoyoung MD | CytomX Therapeutics | 56 | |
| Christopher Garcia | Surrozen | N/A | |
| Rowena Albanna | Aditxt Inc | 59 | |
| Amro Albanna | Aditxt Inc | 55 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 41 | |
| David MD | Passage Bio | N/A | |
| Christopher Ogden | CytomX Therapeutics | 41 | |
| WenChen MD | Surrozen | 60 | |
| Jack Gold | Absci Corp | N/A | |
| Denise Dettore | Absci Corp | N/A | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Roeland Nusse | Surrozen | 75 | |
| DDS MS | Aditxt Inc | 59 | |
| Andreas Busch | Absci Corp | 62 | |
| Thomas JD | Absci Corp | N/A | |
| Jim Wang | Adverum Biotechnologies | N/A | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Steven Martin | Armata Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 |
Oncternal Therapeutics Leadership Team
Elected by the shareholders, the Oncternal Therapeutics' board of directors comprises two types of representatives: Oncternal Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncternal. The board's role is to monitor Oncternal Therapeutics' management team and ensure that shareholders' interests are well served. Oncternal Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncternal Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pablo Urbaneja, Senior Development | ||
| Anita Wiseth, Senior Resources | ||
| Gunnar Kaufmann, Chief Officer | ||
| Chase JD, General Secretary | ||
| Salim MD, Chief Officer | ||
| Chase Leavitt, General Secretary | ||
| Steven Hamburger, VP Assurance | ||
| Richard CPA, Treasurer CFO | ||
| Rajesh Krishnan, Chief Officer |
Oncternal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncternal Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (12.83 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 12.07 % | ||||
| Number Of Shares Shorted | 14.21 K | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.17 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |